Form 4: CFO Espinoza Sells LGND Shares for Tax Obligations

Ligand Pharmaceuticals CFO Octavio Espinoza disposed of 1,862 shares of common stock to cover tax liabilities related to restricted stock unit settlement.

Summary

• Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals Inc. (LGND), reported a transaction on December 5, 2025.
• He disposed of 1,862 shares of LGND common stock at a price of $184.87 per share.
• This disposition was for the purpose of satisfying tax liabilities arising from the settlement of restricted stock units.
• Following this transaction, Mr. Espinoza beneficially owns 27,990 shares of LGND common stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While it's a 'sale', it's non-discretionary and for tax purposes related to RSU vesting, which implies compensation was earned.

Positives

• The transaction represents shares withheld to cover tax liabilities from the settlement of restricted stock units, indicating the vesting of executive compensation.

Negatives

• A reduction of 1,862 shares in direct beneficial ownership by a key executive.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Minor reduction in executive direct ownership, but the transaction is non-discretionary and related to earned compensation.
• Employees: Indicates standard executive compensation practices are in effect.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a non-discretionary sale of shares by the CFO to cover tax obligations related to restricted stock unit vesting. Such routine transactions do not typically indicate a change in management's outlook or the company's fundamentals, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Ligand Pharmaceuticals, LGND, Octavio Espinoza, CFO, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding